News
Kamada Partners with Nebulizer Company on Inhaled AAT
NESS ZIONA, Israel—Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, signed two new strategic development agreements with PARI Pharma, a world leader in inhalation solutions.
One of these agreements is for the conjoint clinical development of aerosolized AAT for treating the indications of Cystic Fibrosis (CF) and Bronchiectasis, in addition to Alpha-1 Antitrypsin Deficiency (AATD). Under the agreement PARI grants Kamada an exclusive license to use an optimized eFlow® Electronic Nebulizer to deliver AAT in its clinical trials also for these indications.
The other agreement is a long term agreement to supply the optimized eFlow® for the marketing, distribution, and commercialization of Kamada’s AAT, pending successful conclusion of the clinical trials.
